DE60307881D1 - Positionelle isomeren von pegyliertem interferon alpha 2a - Google Patents

Positionelle isomeren von pegyliertem interferon alpha 2a

Info

Publication number
DE60307881D1
DE60307881D1 DE60307881T DE60307881T DE60307881D1 DE 60307881 D1 DE60307881 D1 DE 60307881D1 DE 60307881 T DE60307881 T DE 60307881T DE 60307881 T DE60307881 T DE 60307881T DE 60307881 D1 DE60307881 D1 DE 60307881D1
Authority
DE
Germany
Prior art keywords
interferon alpha
pegylated interferon
positional isomers
isomers
positional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60307881T
Other languages
English (en)
Other versions
DE60307881T2 (de
Inventor
Doris Brugger
Stefan Foser
Alfred Schacher
Karl Weyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60307881D1 publication Critical patent/DE60307881D1/de
Application granted granted Critical
Publication of DE60307881T2 publication Critical patent/DE60307881T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60307881T 2002-11-15 2003-11-10 Positionelle isomeren von pegyliertem interferon alpha 2a Expired - Lifetime DE60307881T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15
EP02025585 2002-11-15
PCT/EP2003/012498 WO2004045648A1 (en) 2002-11-15 2003-11-10 Positional isomers of peg ifn alpha 2a

Publications (2)

Publication Number Publication Date
DE60307881D1 true DE60307881D1 (de) 2006-10-05
DE60307881T2 DE60307881T2 (de) 2007-03-08

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60307881T Expired - Lifetime DE60307881T2 (de) 2002-11-15 2003-11-10 Positionelle isomeren von pegyliertem interferon alpha 2a

Country Status (23)

Country Link
US (1) US20040223950A1 (de)
EP (1) EP1562634B1 (de)
JP (1) JP4279258B2 (de)
KR (1) KR20050065677A (de)
CN (1) CN1323722C (de)
AR (1) AR042039A1 (de)
AT (1) ATE337017T1 (de)
AU (1) AU2003293668A1 (de)
BR (1) BR0316227A (de)
CA (1) CA2503594C (de)
DE (1) DE60307881T2 (de)
ES (1) ES2270152T3 (de)
GT (1) GT200300244A (de)
MX (1) MXPA05005178A (de)
NO (1) NO20052310L (de)
PA (1) PA8587801A1 (de)
PE (1) PE20040834A1 (de)
PL (1) PL376883A1 (de)
RU (1) RU2005118752A (de)
TW (1) TW200413404A (de)
UY (1) UY28080A1 (de)
WO (1) WO2004045648A1 (de)
ZA (1) ZA200503756B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
KR20050086498A (ko) * 2002-11-18 2005-08-30 맥시겐, 인크. 인터페론-알파 폴리펩티드 및 접합체
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
AU2006262151A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2009030066A1 (fr) * 2007-09-04 2009-03-12 Biosteed Gene Expression Tech. Co., Ltd. Interféron alpha 2b modifié par du polyethylèneglycol et procédé de préparation et applications associés
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
PL2272875T3 (pl) * 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania
EP2113256A1 (de) 2008-04-29 2009-11-04 Ascendis Pharma AS Pegylierte rhGH-Verbindungen
ES2875426T3 (es) 2008-04-29 2021-11-10 Ascendis Pharma Endocrinology Div A/S Compuestos de hormona de crecimiento humana recombinante pegilada
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
JP2006508918A (ja) * 2002-09-05 2006-03-16 ザ ジェネラル ホスピタル コーポレーション 修飾されたアシアロインターフェロンおよびその使用

Also Published As

Publication number Publication date
JP2006515571A (ja) 2006-06-01
PE20040834A1 (es) 2004-11-17
PL376883A1 (pl) 2006-01-09
US20040223950A1 (en) 2004-11-11
KR20050065677A (ko) 2005-06-29
BR0316227A (pt) 2005-10-04
GT200300244A (es) 2004-06-03
JP4279258B2 (ja) 2009-06-17
CA2503594A1 (en) 2004-06-03
EP1562634B1 (de) 2006-08-23
ZA200503756B (en) 2008-02-27
ES2270152T3 (es) 2007-04-01
EP1562634A1 (de) 2005-08-17
CA2503594C (en) 2011-05-10
WO2004045648A1 (en) 2004-06-03
MXPA05005178A (es) 2005-07-22
NO20052310D0 (no) 2005-05-11
ATE337017T1 (de) 2006-09-15
NO20052310L (no) 2005-08-09
AU2003293668A1 (en) 2004-06-15
PA8587801A1 (es) 2004-09-16
AR042039A1 (es) 2005-06-08
UY28080A1 (es) 2004-05-31
DE60307881T2 (de) 2007-03-08
CN1711109A (zh) 2005-12-21
TW200413404A (en) 2004-08-01
CN1323722C (zh) 2007-07-04
RU2005118752A (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
ATE337017T1 (de) Positionelle isomeren von pegyliertem interferon alpha 2a
DK1543038T4 (da) Proteinoprensning
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
DE60318769D1 (de) Maskenüberzug
ATE489401T1 (de) Pegyliertes t20-polypeptid
NO20034432D0 (no) Interferon gamma polypeptidvarianter
ITMI20022022A1 (it) Analoghi di nocicettina.
ATE474824T1 (de) Herstellung von olefinen
IS7943A (is) Ný amínóbensófenónefnasambönd
EE200200693A (et) Interferoon hulgiskleroosi raviks
ITBO20020206A0 (it) Vasca idromassaggio
DE60312270D1 (de) Bowlingbahn
DE60213222D1 (de) Anrufzentrale
DE50205590D1 (de) Ummantelung von leiterbahnen
DE60227914D1 (de) Extraktive aufreinigung von lipopeptidantibiotika
DE60333790D1 (de) Tetramerisierung von olefinen
ITTS20020014A1 (it) Montaggio rapido rinhiere
FIU20020437U0 (fi) Leikkopuun jalka
FIU20010328U0 (fi) Leikkopuun jalka
DE60307436D1 (de) Reinigung von citalopram
EE00386U1 (et) Pneumohall-bassein
UA6675S (uk) Комплект етикеток
UA7077S (uk) Комплект етикеток
UA6562S (uk) Комплект етикеток
UA7370S (uk) Комплект етикеток

Legal Events

Date Code Title Description
8364 No opposition during term of opposition